Clover Vitality

Clover Vitality pursues early-stage and growth equity investments in healthcare technology companies. The firm focuses on AI and machine learning applications that improve clinical workflows, diagnostic accuracy, and healthcare operations. It targets companies with existing US commercial traction, structuring direct equity investments rather than fund-of-funds commitments.

The firm's Evanston, Illinois headquarters positions it near major Midwestern academic medical centers and health systems, which can serve as pilot sites and early adopters for health-tech companies. This geographic base offers a sourcing channel distinct from coastal venture hubs. Specific sourcing partnerships or deal origination methods have not been publicly detailed.

Available information points to a direct investment model rather than a fund-of-funds approach. The firm's concentrated healthcare AI focus and private equity structure are consistent with hands-on, direct equity deployment. No fund commitments to external general partners have been disclosed.

Clover Vitality targets early-stage venture rounds through growth equity. The firm seeks companies that have moved beyond concept validation and are demonstrating commercial uptake, fitting the profile of a manager providing expansion capital to health-tech platforms.

Clover Vitality has not published an explicit avoidance list, but its self-described focus on AI-driven healthcare technology implies it does not invest in therapeutics, medical devices, or healthcare services unrelated to machine learning. Sectors such as biotech drug development, traditional hospital operations, and non-healthcare software appear outside the mandate.

Principals and investment decision-makers have not been publicly identified as of mid-2026. The firm has not listed a founding team, investment committee, or advisory board on its website or in regulatory filings. This opacity is consistent with an early-stage firm that has not yet marketed to limited partners.

Clover Vitality is structured as a private equity manager, not a family office or venture capital firm, though its stage focus overlaps with venture. The firm has not disclosed its legal entity structure, fund formation status, or limited partner composition. A one-page web presence registered in 2024 suggests a manager in the early phases of establishing institutional operations.